Clinical Trial: A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Stage I-III Non-Small Cell Lung Cancer

A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Stage I-III Non-Small Cell Lung Cancer


Sponsor and Collaborators
Dartmouth-Hitchcock Medical Center
Merck

Contact
Konstantin H. Dragnev, MD
(603) 650-6345
konstantin.h.dragnev@hitchcock.org

Brendan M. Slagle, BS
(603) 653-0590
brendan.m.slagle@dartmouth.edu

Principal Investigator
Konstantin H. Dragnev, MD
Dartmouth-Hitchcock Medical Center

Clinical Trials.gov Identifier

NCT00735826
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs